Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 55 | 2023 | 4838 | 2.950 |
Why?
|
Endometrial Neoplasms | 10 | 2021 | 1353 | 1.190 |
Why?
|
Peritoneal Neoplasms | 11 | 2023 | 665 | 1.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 2 | 2019 | 241 | 0.990 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 33 | 2020 | 11524 | 0.980 |
Why?
|
Genital Neoplasms, Female | 5 | 2023 | 523 | 0.870 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2020 | 9239 | 0.860 |
Why?
|
Taxoids | 10 | 2013 | 666 | 0.800 |
Why?
|
Paclitaxel | 20 | 2014 | 1708 | 0.750 |
Why?
|
Diaphragm | 5 | 2013 | 349 | 0.680 |
Why?
|
Gynecologic Surgical Procedures | 5 | 2014 | 336 | 0.680 |
Why?
|
Vulvar Neoplasms | 4 | 2022 | 272 | 0.620 |
Why?
|
Neoplasms, Glandular and Epithelial | 6 | 2015 | 484 | 0.560 |
Why?
|
Pelvic Exenteration | 3 | 2014 | 22 | 0.520 |
Why?
|
Antineoplastic Agents, Phytogenic | 6 | 2000 | 624 | 0.520 |
Why?
|
Camptothecin | 3 | 2004 | 576 | 0.490 |
Why?
|
Antineoplastic Agents | 22 | 2016 | 13695 | 0.490 |
Why?
|
Neoplasm Staging | 29 | 2023 | 11031 | 0.460 |
Why?
|
Neoplasm, Residual | 4 | 2014 | 973 | 0.460 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 255 | 0.460 |
Why?
|
Angiogenesis Inhibitors | 4 | 2015 | 2038 | 0.450 |
Why?
|
Uterine Cervical Neoplasms | 8 | 2020 | 2020 | 0.400 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2728 | 0.370 |
Why?
|
Laparotomy | 2 | 2016 | 473 | 0.360 |
Why?
|
Carboplatin | 11 | 2014 | 801 | 0.360 |
Why?
|
Fallopian Tube Neoplasms | 6 | 2011 | 324 | 0.350 |
Why?
|
Drug Administration Schedule | 21 | 2013 | 4933 | 0.340 |
Why?
|
Lymph Node Excision | 7 | 2022 | 1261 | 0.330 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2023 | 450 | 0.330 |
Why?
|
Female | 116 | 2023 | 380194 | 0.320 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2727 | 0.310 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2001 | 5221 | 0.300 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 1125 | 0.300 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 1876 | 0.300 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 17446 | 0.300 |
Why?
|
Middle Aged | 86 | 2021 | 213383 | 0.290 |
Why?
|
Dacarbazine | 2 | 2006 | 566 | 0.290 |
Why?
|
Aged | 77 | 2021 | 163280 | 0.290 |
Why?
|
Hysterectomy | 5 | 2021 | 927 | 0.280 |
Why?
|
Mixed Tumor, Mullerian | 1 | 2006 | 56 | 0.280 |
Why?
|
Phosphorylcholine | 1 | 2006 | 162 | 0.270 |
Why?
|
Carcinoma, Endometrioid | 2 | 2021 | 271 | 0.270 |
Why?
|
Muscle Neoplasms | 1 | 2006 | 139 | 0.260 |
Why?
|
Abdominal Fat | 1 | 2007 | 223 | 0.260 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3086 | 0.260 |
Why?
|
Disease-Free Survival | 15 | 2015 | 6895 | 0.260 |
Why?
|
Pleural Effusion | 2 | 2013 | 338 | 0.250 |
Why?
|
Adult | 75 | 2021 | 214055 | 0.240 |
Why?
|
Combined Modality Therapy | 13 | 2014 | 8642 | 0.240 |
Why?
|
Anthraquinones | 2 | 1993 | 37 | 0.230 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2006 | 627 | 0.230 |
Why?
|
Infusions, Intravenous | 10 | 2011 | 2274 | 0.230 |
Why?
|
Leiomyosarcoma | 2 | 2021 | 477 | 0.230 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2023 | 59 | 0.230 |
Why?
|
Humans | 121 | 2023 | 744343 | 0.220 |
Why?
|
Lung Neoplasms | 14 | 2001 | 13102 | 0.220 |
Why?
|
Guanine | 2 | 2001 | 274 | 0.220 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2000 | 692 | 0.220 |
Why?
|
Immunotherapy | 1 | 2018 | 4445 | 0.220 |
Why?
|
Ovariectomy | 3 | 2014 | 661 | 0.210 |
Why?
|
Survival Rate | 18 | 2018 | 12788 | 0.210 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5535 | 0.200 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2022 | 709 | 0.180 |
Why?
|
Doxorubicin | 3 | 2012 | 2234 | 0.180 |
Why?
|
Topotecan | 6 | 2013 | 137 | 0.180 |
Why?
|
Deoxycytidine | 4 | 2014 | 826 | 0.180 |
Why?
|
Cisplatin | 9 | 2013 | 1662 | 0.180 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2020 | 44 | 0.180 |
Why?
|
Phenyl Ethers | 1 | 1999 | 58 | 0.180 |
Why?
|
Interferon-alpha | 4 | 2000 | 895 | 0.180 |
Why?
|
Receptors, Growth Factor | 1 | 2001 | 334 | 0.180 |
Why?
|
Melanoma | 1 | 2018 | 5510 | 0.180 |
Why?
|
Lymph Nodes | 3 | 2022 | 3474 | 0.170 |
Why?
|
Histamine Antagonists | 1 | 1999 | 93 | 0.170 |
Why?
|
Ifosfamide | 4 | 1998 | 228 | 0.170 |
Why?
|
Sarcoma | 2 | 2006 | 1897 | 0.160 |
Why?
|
Aged, 80 and over | 22 | 2021 | 57776 | 0.160 |
Why?
|
Uterine Neoplasms | 2 | 2021 | 1513 | 0.160 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2021 | 360 | 0.160 |
Why?
|
Organoplatinum Compounds | 4 | 2010 | 408 | 0.160 |
Why?
|
Neoplasms | 8 | 2006 | 21683 | 0.160 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2001 | 629 | 0.160 |
Why?
|
Treatment Outcome | 30 | 2020 | 63114 | 0.160 |
Why?
|
Maximum Tolerated Dose | 2 | 2014 | 892 | 0.150 |
Why?
|
Tretinoin | 1 | 2000 | 517 | 0.150 |
Why?
|
Canada | 8 | 2006 | 2065 | 0.150 |
Why?
|
Depsipeptides | 1 | 1998 | 94 | 0.150 |
Why?
|
Ontario | 1 | 2018 | 383 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2013 | 5172 | 0.150 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1999 | 358 | 0.140 |
Why?
|
Medical Oncology | 2 | 2016 | 2265 | 0.140 |
Why?
|
Robotics | 2 | 2015 | 899 | 0.140 |
Why?
|
Genetic Counseling | 1 | 2020 | 600 | 0.140 |
Why?
|
Obesity, Morbid | 1 | 2007 | 1213 | 0.140 |
Why?
|
Aminoquinolines | 1 | 2016 | 109 | 0.140 |
Why?
|
Survival Analysis | 9 | 2012 | 10252 | 0.140 |
Why?
|
Paget Disease, Extramammary | 1 | 2016 | 45 | 0.140 |
Why?
|
Retrospective Studies | 23 | 2023 | 77449 | 0.130 |
Why?
|
Leukemia, Myeloid | 1 | 1999 | 707 | 0.130 |
Why?
|
Leiomyoma | 1 | 2021 | 730 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2011 | 10943 | 0.130 |
Why?
|
Peptides, Cyclic | 1 | 1998 | 400 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 648 | 0.130 |
Why?
|
Laparoscopy | 1 | 2007 | 2151 | 0.130 |
Why?
|
DNA Repair | 1 | 2024 | 2046 | 0.120 |
Why?
|
Statistics as Topic | 1 | 2001 | 2373 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2021 | 975 | 0.120 |
Why?
|
New York City | 2 | 2006 | 710 | 0.120 |
Why?
|
Vaginal Neoplasms | 1 | 2014 | 106 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 934 | 0.110 |
Why?
|
Benzhydryl Compounds | 1 | 1999 | 845 | 0.110 |
Why?
|
Aminoglycosides | 1 | 1994 | 162 | 0.110 |
Why?
|
Social Support | 1 | 2023 | 2118 | 0.110 |
Why?
|
Histone Deacetylase 1 | 1 | 2013 | 137 | 0.110 |
Why?
|
Pyrazoles | 2 | 1993 | 1972 | 0.110 |
Why?
|
Agranulocytosis | 3 | 2000 | 101 | 0.110 |
Why?
|
Parity | 1 | 2016 | 929 | 0.110 |
Why?
|
Piperidones | 1 | 2012 | 28 | 0.110 |
Why?
|
Psychometrics | 1 | 2021 | 3002 | 0.100 |
Why?
|
Perioperative Care | 1 | 2020 | 1002 | 0.100 |
Why?
|
Colostomy | 1 | 2012 | 99 | 0.100 |
Why?
|
Urinary Diversion | 1 | 2012 | 138 | 0.100 |
Why?
|
BRCA1 Protein | 2 | 2024 | 1149 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2000 | 1580 | 0.100 |
Why?
|
Astrocytoma | 1 | 1996 | 790 | 0.100 |
Why?
|
Pentostatin | 2 | 2000 | 26 | 0.100 |
Why?
|
Reproduction | 1 | 2016 | 668 | 0.100 |
Why?
|
Carcinoma | 2 | 2001 | 2375 | 0.090 |
Why?
|
Fertility | 1 | 2016 | 781 | 0.090 |
Why?
|
Intraoperative Care | 1 | 2014 | 767 | 0.090 |
Why?
|
Isoxazoles | 3 | 1990 | 216 | 0.090 |
Why?
|
Splenectomy | 2 | 2008 | 395 | 0.090 |
Why?
|
Leukemia, Hairy Cell | 2 | 2000 | 82 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3616 | 0.090 |
Why?
|
Prognosis | 6 | 2020 | 29063 | 0.090 |
Why?
|
Feasibility Studies | 4 | 2014 | 5078 | 0.090 |
Why?
|
Palliative Care | 4 | 2018 | 3493 | 0.090 |
Why?
|
Documentation | 1 | 2016 | 871 | 0.090 |
Why?
|
Breast Neoplasms | 5 | 2006 | 20822 | 0.080 |
Why?
|
Intestinal Obstruction | 1 | 2013 | 424 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2023 | 3479 | 0.080 |
Why?
|
Glutamates | 2 | 2001 | 398 | 0.080 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2013 | 332 | 0.080 |
Why?
|
Injections, Intravenous | 5 | 2006 | 1420 | 0.080 |
Why?
|
CA-125 Antigen | 2 | 2009 | 286 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1676 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2014 | 6489 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2016 | 39050 | 0.080 |
Why?
|
Quality of Life | 9 | 2023 | 12804 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2043 | 0.080 |
Why?
|
Prospective Studies | 10 | 2023 | 53288 | 0.080 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 873 | 0.080 |
Why?
|
Carcinoma, Small Cell | 3 | 1999 | 420 | 0.080 |
Why?
|
Decompression, Surgical | 1 | 2013 | 594 | 0.080 |
Why?
|
Pancreatic Fistula | 1 | 2008 | 146 | 0.080 |
Why?
|
Etoposide | 3 | 1999 | 641 | 0.080 |
Why?
|
Disease Progression | 6 | 2013 | 13284 | 0.080 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3158 | 0.080 |
Why?
|
Databases, Factual | 3 | 2008 | 7729 | 0.080 |
Why?
|
Kidney Neoplasms | 3 | 2000 | 4262 | 0.070 |
Why?
|
Anxiety | 1 | 2021 | 4297 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 2 | 2000 | 3143 | 0.070 |
Why?
|
Neoplasm Metastasis | 3 | 2006 | 4851 | 0.070 |
Why?
|
Pancreatectomy | 2 | 2008 | 804 | 0.070 |
Why?
|
Referral and Consultation | 2 | 2020 | 3528 | 0.070 |
Why?
|
Oxazoles | 2 | 1986 | 189 | 0.070 |
Why?
|
Abdominal Neoplasms | 1 | 2008 | 292 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4034 | 0.070 |
Why?
|
Omentum | 1 | 2007 | 170 | 0.070 |
Why?
|
Male | 31 | 2018 | 350118 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1434 | 0.070 |
Why?
|
Carmustine | 1 | 2006 | 137 | 0.070 |
Why?
|
Remission Induction | 4 | 2000 | 2386 | 0.070 |
Why?
|
Young Adult | 6 | 2021 | 56430 | 0.070 |
Why?
|
Infusions, Parenteral | 3 | 2006 | 419 | 0.070 |
Why?
|
Brain Neoplasms | 3 | 1996 | 8863 | 0.070 |
Why?
|
Lymphatic Metastasis | 3 | 2022 | 2924 | 0.070 |
Why?
|
Nomograms | 1 | 2007 | 228 | 0.070 |
Why?
|
Pain, Postoperative | 1 | 2016 | 1643 | 0.070 |
Why?
|
Abdomen | 2 | 2008 | 1118 | 0.070 |
Why?
|
Peritoneum | 1 | 2006 | 228 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 2 | 2016 | 4554 | 0.060 |
Why?
|
Academies and Institutes | 1 | 2006 | 317 | 0.060 |
Why?
|
Platinum Compounds | 2 | 2009 | 96 | 0.060 |
Why?
|
Cohort Studies | 6 | 2022 | 40561 | 0.060 |
Why?
|
DNA Damage | 1 | 2013 | 2432 | 0.060 |
Why?
|
Rad51 Recombinase | 1 | 2024 | 189 | 0.060 |
Why?
|
Postoperative Care | 2 | 2007 | 1486 | 0.060 |
Why?
|
Neutropenia | 4 | 2000 | 895 | 0.060 |
Why?
|
Length of Stay | 2 | 2015 | 6309 | 0.060 |
Why?
|
Thionucleotides | 1 | 2003 | 107 | 0.060 |
Why?
|
Half-Life | 1 | 2004 | 661 | 0.060 |
Why?
|
Drug Evaluation | 6 | 1992 | 647 | 0.060 |
Why?
|
Glioblastoma | 2 | 1996 | 3481 | 0.060 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 57 | 0.060 |
Why?
|
Inpatients | 1 | 2015 | 2518 | 0.060 |
Why?
|
Prevalence | 1 | 2019 | 15226 | 0.050 |
Why?
|
Medical Records | 1 | 2007 | 1413 | 0.050 |
Why?
|
Nausea | 3 | 2000 | 673 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6538 | 0.050 |
Why?
|
Folic Acid Antagonists | 1 | 2001 | 84 | 0.050 |
Why?
|
Liposomes | 1 | 2004 | 759 | 0.050 |
Why?
|
Glioma | 1 | 1996 | 3401 | 0.050 |
Why?
|
Endometrial Hyperplasia | 1 | 2021 | 97 | 0.050 |
Why?
|
Colorectal Neoplasms | 2 | 2006 | 6773 | 0.050 |
Why?
|
Spleen | 1 | 2006 | 2362 | 0.050 |
Why?
|
Area Under Curve | 1 | 2004 | 1654 | 0.050 |
Why?
|
Amifostine | 1 | 1999 | 41 | 0.040 |
Why?
|
Fever | 2 | 2013 | 1616 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 1989 | 1363 | 0.040 |
Why?
|
Analgesics, Opioid | 1 | 2016 | 3674 | 0.040 |
Why?
|
Administration, Oral | 2 | 2006 | 3913 | 0.040 |
Why?
|
Pancreas | 1 | 2006 | 1686 | 0.040 |
Why?
|
Radiation-Protective Agents | 1 | 1999 | 90 | 0.040 |
Why?
|
Apoptosis | 2 | 2013 | 9727 | 0.040 |
Why?
|
Patient Selection | 2 | 2015 | 4215 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2024 | 594 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2021 | 221 | 0.040 |
Why?
|
Nitriles | 1 | 2004 | 956 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2006 | 1275 | 0.040 |
Why?
|
Epirubicin | 2 | 2012 | 80 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2016 | 7880 | 0.040 |
Why?
|
United States | 6 | 2023 | 69872 | 0.040 |
Why?
|
Triazoles | 1 | 2004 | 911 | 0.040 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1999 | 121 | 0.040 |
Why?
|
Recombinant Proteins | 5 | 2000 | 6622 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 379 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2017 | 68 | 0.040 |
Why?
|
Quality Indicators, Health Care | 1 | 2007 | 1831 | 0.040 |
Why?
|
Diphenhydramine | 1 | 1996 | 63 | 0.040 |
Why?
|
Drug Synergism | 1 | 2000 | 1792 | 0.030 |
Why?
|
Fatigue | 2 | 2000 | 1531 | 0.030 |
Why?
|
Risk Factors | 3 | 2019 | 72290 | 0.030 |
Why?
|
Postoperative Period | 2 | 2013 | 1842 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9648 | 0.030 |
Why?
|
Antiemetics | 1 | 1998 | 177 | 0.030 |
Why?
|
Retroperitoneal Space | 1 | 2016 | 176 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2013 | 1770 | 0.030 |
Why?
|
Granulocytes | 1 | 1998 | 548 | 0.030 |
Why?
|
Paresthesia | 1 | 1996 | 161 | 0.030 |
Why?
|
Neoplasms, Second Primary | 2 | 2000 | 1061 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2017 | 9959 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 1994 | 7181 | 0.030 |
Why?
|
Ethics, Medical | 1 | 2001 | 792 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 806 | 0.030 |
Why?
|
Hematuria | 1 | 1996 | 235 | 0.030 |
Why?
|
Rectal Neoplasms | 1 | 1984 | 1206 | 0.030 |
Why?
|
Radiography | 1 | 2006 | 7023 | 0.030 |
Why?
|
Drug Tolerance | 1 | 1996 | 376 | 0.030 |
Why?
|
Nephrectomy | 1 | 2000 | 1050 | 0.030 |
Why?
|
Confusion | 1 | 1996 | 275 | 0.030 |
Why?
|
Treatment Failure | 1 | 2000 | 2618 | 0.030 |
Why?
|
Liver | 2 | 2008 | 7474 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 690 | 0.030 |
Why?
|
Risk Assessment | 1 | 2016 | 23338 | 0.030 |
Why?
|
Pregnancy | 1 | 2016 | 29144 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2005 | 7913 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 841 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2010 | 21746 | 0.030 |
Why?
|
Diarrhea | 1 | 2000 | 1348 | 0.030 |
Why?
|
Thoracostomy | 1 | 2013 | 72 | 0.030 |
Why?
|
Isotretinoin | 1 | 1994 | 114 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2001 | 1660 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2001 | 1741 | 0.030 |
Why?
|
Cyclic S-Oxides | 1 | 2012 | 21 | 0.030 |
Why?
|
Hematologic Tests | 1 | 1993 | 240 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 1984 | 2541 | 0.030 |
Why?
|
Arthralgia | 1 | 1996 | 456 | 0.030 |
Why?
|
Muscular Diseases | 1 | 1996 | 556 | 0.030 |
Why?
|
Interleukin-3 | 1 | 1993 | 444 | 0.030 |
Why?
|
Forecasting | 2 | 2005 | 2951 | 0.030 |
Why?
|
Postoperative Complications | 3 | 2016 | 15295 | 0.030 |
Why?
|
Parenteral Nutrition, Total | 1 | 2013 | 302 | 0.030 |
Why?
|
Chemokines | 1 | 2016 | 970 | 0.020 |
Why?
|
Ribavirin | 1 | 1993 | 395 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2016 | 1000 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2001 | 2716 | 0.020 |
Why?
|
Sulfonylurea Compounds | 1 | 1992 | 204 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2012 | 463 | 0.020 |
Why?
|
Cyclophosphamide | 2 | 2013 | 2242 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1994 | 640 | 0.020 |
Why?
|
Government Agencies | 1 | 1990 | 156 | 0.020 |
Why?
|
Age Factors | 1 | 2007 | 18370 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2012 | 2503 | 0.020 |
Why?
|
Urinary Tract | 1 | 2013 | 309 | 0.020 |
Why?
|
Pilot Projects | 2 | 2016 | 8324 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7301 | 0.020 |
Why?
|
Drug Design | 1 | 2015 | 1076 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2012 | 730 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2459 | 0.020 |
Why?
|
Dexamethasone | 1 | 1996 | 1951 | 0.020 |
Why?
|
Hematologic Diseases | 3 | 1996 | 498 | 0.020 |
Why?
|
Drug Hypersensitivity | 1 | 1998 | 884 | 0.020 |
Why?
|
Amylases | 1 | 2008 | 173 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8663 | 0.020 |
Why?
|
Bone Marrow | 1 | 1999 | 2948 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 2008 | 148 | 0.020 |
Why?
|
Pain | 2 | 2000 | 4986 | 0.020 |
Why?
|
Acute Disease | 1 | 1999 | 7149 | 0.020 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1991 | 903 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4751 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 12354 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5179 | 0.020 |
Why?
|
Incidence | 1 | 2006 | 20947 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 6314 | 0.020 |
Why?
|
Oncology Service, Hospital | 1 | 2007 | 57 | 0.020 |
Why?
|
BRCA2 Protein | 1 | 2012 | 794 | 0.020 |
Why?
|
Outpatients | 1 | 2015 | 1486 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4149 | 0.020 |
Why?
|
Vomiting | 2 | 2000 | 636 | 0.020 |
Why?
|
Time Factors | 2 | 2009 | 40075 | 0.020 |
Why?
|
Ascites | 1 | 2008 | 344 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2013 | 16689 | 0.020 |
Why?
|
Second-Look Surgery | 1 | 2006 | 29 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2012 | 1182 | 0.020 |
Why?
|
Down-Regulation | 1 | 2013 | 3002 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12959 | 0.020 |
Why?
|
Transfection | 1 | 2013 | 5892 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2916 | 0.020 |
Why?
|
Research Design | 1 | 2001 | 5987 | 0.020 |
Why?
|
Adenocarcinoma | 2 | 2017 | 6364 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2635 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2012 | 2077 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2013 | 4204 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2016 | 0.020 |
Why?
|
Genes, bcl-2 | 1 | 2004 | 122 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 1990 | 0.010 |
Why?
|
Genes, erbB-2 | 1 | 2004 | 162 | 0.010 |
Why?
|
Epithelial Cells | 2 | 2006 | 3690 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 1677 | 0.010 |
Why?
|
Risk Adjustment | 1 | 2007 | 594 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2016 | 3396 | 0.010 |
Why?
|
Histones | 1 | 2013 | 2599 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 2011 | 9274 | 0.010 |
Why?
|
Drainage | 1 | 2008 | 1142 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 2645 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1990 | 1179 | 0.010 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2004 | 431 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5882 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2013 | 5867 | 0.010 |
Why?
|
Patient Compliance | 1 | 2012 | 2684 | 0.010 |
Why?
|
Physical Examination | 1 | 2007 | 1237 | 0.010 |
Why?
|
Phosphorylation | 1 | 2012 | 8436 | 0.010 |
Why?
|
Brachytherapy | 1 | 2008 | 1248 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 13033 | 0.010 |
Why?
|
Cladribine | 1 | 2000 | 34 | 0.010 |
Why?
|
Medication Adherence | 1 | 2012 | 2063 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1992 | 4420 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 1984 | 518 | 0.010 |
Why?
|
Platelet Count | 2 | 1993 | 781 | 0.010 |
Why?
|
Patient Readmission | 1 | 2013 | 3114 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 3 | 2013 | 20129 | 0.010 |
Why?
|
Survivors | 1 | 2009 | 2291 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2004 | 1142 | 0.010 |
Why?
|
Adolescent | 3 | 1998 | 85781 | 0.010 |
Why?
|
Body Mass Index | 1 | 2015 | 12720 | 0.010 |
Why?
|
Models, Biological | 1 | 1993 | 9583 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 6234 | 0.010 |
Why?
|
Cough | 1 | 2000 | 555 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10481 | 0.010 |
Why?
|
Epithelium | 1 | 2000 | 1679 | 0.010 |
Why?
|
Alopecia | 1 | 1999 | 382 | 0.010 |
Why?
|
Lymphopenia | 1 | 1997 | 285 | 0.010 |
Why?
|
Postmenopause | 1 | 2004 | 2461 | 0.010 |
Why?
|
Kidney | 1 | 1990 | 7186 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 35421 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2004 | 2849 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2004 | 2948 | 0.010 |
Why?
|
Mood Disorders | 1 | 2000 | 1106 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15076 | 0.010 |
Why?
|
Dyspnea | 1 | 2000 | 1303 | 0.010 |
Why?
|
Premedication | 1 | 1993 | 258 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2007 | 4371 | 0.010 |
Why?
|
Platinum | 1 | 1993 | 233 | 0.010 |
Why?
|
Neutrophils | 2 | 1993 | 3719 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3584 | 0.010 |
Why?
|
Leukopenia | 1 | 1988 | 212 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1991 | 1588 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 2000 | 13989 | 0.000 |
Why?
|
Animals | 1 | 2015 | 168757 | 0.000 |
Why?
|
Heart Rate | 1 | 1993 | 4091 | 0.000 |
Why?
|
Blood Pressure | 1 | 1993 | 8554 | 0.000 |
Why?
|
Cognition Disorders | 1 | 1986 | 4043 | 0.000 |
Why?
|